Genentech Sues Sandoz Over Generic Valcyte
Genentech and Roche Palo Alto LLC's complaint claims Sandoz — the generics arm of Novartis AG — infringed the patent-in-suit by seeking U.S. Food and Drug Administration approval for a generic version of Valcyte, and seeks to block Sandoz from selling its generic in the U.S. before that patent expires.
Sandoz’s product infringes the Roche crystalline valganciclovir patent, Roche said in a statement,...
Already a subscriber? Click here to login